skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Can you please shed some light on why CXR is down 8% since the call this morning? I thought the call was positive and it helped to break the correlation to Valeant's business issues. What on the call is being interpreted so negatively by the markets? This doesn't impact my decision to hold long term as I got in at a very high price, just trying to educate myself on market moves. Thanks again and again...John C.
Read Answer Asked by john on March 24, 2016
Q: Hello.
As most, I am not accustom to having my capital cut by 25% in 4 days like I have experienced with CXR. My bad for being drawn into this type of investment.
As I am here now, I was expecting to see someone ask for your market experienced comment on what we just witnessed this week and how to deal with it.....as I wonder what is next.
Is there a story that goes with this cut in share price? (Wise and Seasoned Investors getting out before earnings?) Or do we just sit blindly believing it is all due to Valiant?
Appreciate your input.
Thanks

Read Answer Asked by Dave on March 21, 2016
Q: CXR is really testing my patience.
I understand that there's a guilt by association issue concerning what's going on with VRX. Wouldn't the market realize this? CXR is down over 60% from its high's. The way I see this means one of two things. They too have accounting issue's....or...the stock is an incredible buying opportunity. Could you please bring some light to the present situation. Thanks
Nicholas
Read Answer Asked by nicholas on March 17, 2016
Q: Concordia reports Q4('15) on March 23 and TD shows Non GAAP EPS of $1.46 (7 analyst average). Not sure if this is an upgrade from your Jan.27 estimate of $1.12 (GAAP?) or if currency conversion is in play because they report in US$ or it's Bloomberg numbers vs Broker's?

As Ryan mentions in the Oct. blog piece on CRX leverage is the issue to focus on so if they hit their 2016 numbers of ~$6.50 US how much of their $3.48 US BB debt would you expect them to pay down by end of 2016 FY and could this remove the "mini Valeant" tag if they were able to pay down a bunch? Thanks, J.
Read Answer Asked by Jeff on March 07, 2016
Q: Hi Peter, Considering current downturn in biotechs and future overhang of US elections, do you think I would be better off to wait until August/September this year to pick up CXR or NHC? Also I read biotech prices are inversely proportional to interest rates. So do you think it is a good bet to hold CXR at this time when fed is tightening? I have 30% of my portfolio in cash. Should I hold off until August or September(weakest month)to deploy them for a 10 year hold?
Read Answer Asked by Sridip on February 09, 2016
Q: Thoughts on CXR looking very attractively priced at the moment? They've got enough international exposure to their business that any action in the US to lower drug prices (which would likely take a new government and years to pass legislation) would not have a significant impact on CXR's business. Clinton's new video against Valeant and people panicking and selling CXR seem to be providing a great entry point.
Read Answer Asked by Arneh on January 29, 2016
Q: Re Dennis question on CXR
Scotia itrade actually has CXR as a sector outperform with a target of $75 (see company Edge report). Dennis may be looking at something called Research Team report which is a separate service that Scotia includes on their site. They do have it as a sell but it is only 4 analysts, and their accuracy was poor in 2015 as note on the very bottom of the report. It is not the Scotiabank opinion.
I bought some CXR based on the 5 i - Ryan M blog at under forty and sold at $50 ( thanks Ryan!) Will try it again if the price dips below $40 again.
food for thought, Dennis
Read Answer Asked by john on January 25, 2016
Q: Recent downturn the health stocks went down farther than the average other groups. In fact, CXR went from $57 to $38. Now with this rebound, the health stocks seem to be lagging including CXR. On my I-Trade account, the most recent update with CXR in January, they have it listed as a sell. Prior to that, they had it listed as a buy. Do you know why this stock is underperforming considering it's been a pick of BNN several times and is in your model portfolio?

Thank you. Your answer will be well appreciated as I have a fair amount of CXR.

Dennis
Read Answer Asked by Dennis on January 25, 2016
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!